High rates of occult fallopian tube cancer diagnosed at prophylactic bilateral salpingo-oophorectomy

International Journal of Gynecological Cancer

Volumn 19, Issue 5, 2009, Pages 826-829

  Hirst, Jane E ^a   Gard, Gregory B ^a   Mcillroy, Kirsty ^a   Nevell, David ^a   Field, Michael ^a  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

BRCA mutation; Fallopian tube neoplasia; Ovarian neoplasia; Prophylactic surgery

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ABDOMINAL HYSTERECTOMY; ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER PATIENT; CANCER PREVENTION; CARCINOMA IN SITU; CASE STUDY; CLINICAL ARTICLE; FEMALE; HETEROZYGOTE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INVASIVE CARCINOMA; LACERATION; LAPAROSCOPIC SURGERY; OCCULT CANCER; OVARY METASTASIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SALPINGOOOPHORECTOMY; TREATMENT OUTCOME; UTERINE TUBE CARCINOMA; VAGINAL HYSTERECTOMY; BREAST TUMOR; CASE REPORT; CYSTADENOCARCINOMA; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; MUTATION; OVARIECTOMY; OVARY TUMOR; PATHOLOGY; RISK FACTOR; TUMOR SUPPRESSOR GENE; UTERINE TUBE TUMOR;

AGED; BREAST NEOPLASMS; CARCINOMA IN SITU; CYSTADENOCARCINOMA, SEROUS; FALLOPIAN TUBE NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; OVARIECTOMY; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 69449107362     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181a1b5dc     Document Type: Article

References (27)

1. Finch A, Beiner M, Lubinski J, et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA. 2006;296:185-192.
2. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast andovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Human Genet. 2003;72:1117-1130.
3. Kauff ND, Domchek SM, Friebel TM, et al. Multi-centre prospective analysis of risk reducing salpingoophorectomy to prevent BRCA-associated breast and ovarian cancer. J Clin Oncol. 2006;24:49s, (suppl, abstr 1003).
4. Eisen A, Lubinski J, Klijn J, et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol. 2005;23:7491-7496. (Pubitemid 46291812)
5. Domchek SM, Rebbeck TR. Prophylactic oophorectomy in women at increased cancer risk. Curr Opin Obstet Gynecol. 2007;19:27-30.
6. Finch A, Shaw P, Rosen B, et al. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gyn Oncol. 2006;100:58-64.
7. Powell CB, Kenley E, Chen LM, et al. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J Clin Oncol. 2005;23:127-132.
8. Deleted in proof.
9. Deleted in proof.
10. Medeiros F, Muto MG, Lee Y, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol. 2006;30:230-236.
11. National Breast and Ovarian Cancer Centre. Advice about familial aspects of breast and epithelial ovarian cancer a guide for health professionals. 2006 www.nbcc.org.au.
12. Kauff ND, Mitra N, Robson ME, et al. Risk of ovarian cancer in BRCA1 and BRCA2 mutation negative hereditary breast cancer families. J Natl Cancer Inst. 2005;97:1382-1384.
13. Lee Y, Medeiros F, Kindelberger D, et al. Advances in the recognition of tubal intraepithelial carcinoma: applications to cancer screening and the pathogenesis of ovarian cancer. Adv Anat Pathol. 2006;13:1-7.
14. Kauff ND, Barakat RR. Risk reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 of BRCA2. J Clin Oncol. 2007;25:2921-2927.
15. Hogg R, Friedlander M. Biology of epithelial ovarian cancer: implications for screening women at high genetic risk. J Clin Oncol. 2004;22:1315-1327.
16. Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. [see comment]. N Engl J Med. 2002;346:1616-1622.
17. Lu KH, Garber JE, Cramer DW, et al. Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. J Clin Oncol. 2000;18:2728-2732.
18. Scheuer L, Kauff N, Robson M, et al. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol. 2002;20:1260-1268.
19. Leeper K, Garcia R, Swisher E, et al. Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol Oncol. 2002;87:52-56.
20. Olivier RI, van Beurden M, Lubsen MA, et al. Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up. Br J Cancer. 2004;90:1492-1497.
21. Callahan MJ, Crum CP, Medeiros F, et al. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol. 2007;25:3985-3990.
22. Lamb JD, Garcia RL, Goff BA, et al. Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy. Am J Obstet Gynecol. 2006;194:1702-1709.
23. Levine DA, Argenta PA, Yee CJ, et al. Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. J Clin Oncol. 2003;21:4222-4227.
24. Carcangiu ML, Peissel B, Pasini B, et al. Incidental carcinomas in prophylactic specimens in BRCA1 and BRCA2 germ-line mutation carriers, with emphasis on fallopian tube lesions: report of 6 cases and review of the literature. Am J Surg Pathol. 2006;30:1222-1230.
25. Aziz S, Kuperstein G, Rosen B, et al. A genetic epidemiological study of carcinoma of the fallopian tube. [see comment]. Gynecol Oncol. 2001;80:341-345.
26. Carcangiu ML, Radice P, Manoukian S, et al. Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers. Int J Gynecol Pathol. 2004;23:35-40.
27. Madalinska JB, Hollenstein J, Bleiker E, et al. Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J Clin Oncol. 2005;23:6890-6898.